Global Blood Therapeutics (GBT) Short Interest Ratio & Short Volume

Short interest is the volume of Global Blood Therapeutics shares that have been sold short but have not yet been covered or closed out. As of September 15th, investors have sold 7,280,000 shares of GBT short. Learn More on Global Blood Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GBT shares currently have a short interest ratio of 2.0. Learn More on Global Blood Therapeutics's short interest ratio.

Global Blood Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 7,280,000 shares, an increase of 5.7% from the previous total of 6,890,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the sector of "medical" compare to Global Blood Therapeutics: United Therapeutics Co. (4.77%), Intra-Cellular Therapies, Inc. (2.58%), Genmab A/S (0.45%), Summit Therapeutics Inc. (29.82%), Insmed Incorporated (9.65%), Dr. Reddy's Laboratories Limited (1.83%), BioMarin Pharmaceutical Inc. (2.38%), Ascendis Pharma A/S (10.33%), Viatris Inc. (4.53%), Blueprint Medicines Co. (9.26%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Occidental Petroleum Co. ($4.11 billion), Canadian Natural Resources Limited ($3.64 billion), Charter Communications, Inc. ($3.15 billion), Lucid Group, Inc. ($2.09 billion), Chesapeake Energy Co. ($2.02 billion), Coinbase Global, Inc. ($2.01 billion), T. Rowe Price Group, Inc. ($1.92 billion), Plug Power Inc. ($1.77 billion), Rivian Automotive, Inc. ($1.71 billion), and Williams-Sonoma, Inc. ($1.59 billion). View all of the most shorted stocks.

Short selling GBT is an investing strategy that aims to generate trading profit from Global Blood Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Global Blood Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GBT, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GBT, twice per month. The most recent reporting period available is September, 15 2022.